evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

480 questions · 484 findings · 52 reviews · Musculoskeletal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 114 · 23.6%GRADE not reported 24 · 5%Very low 33 · 6.8%Low 145 · 30%Moderate 116 · 24%High 52 · 10.7%

Monthly pegloticase vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Total adverse events · participants with tophi in gout

Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Lesinurad 200 mg plus allopurinol vs placebo plus allopurinol

Proportion with complete resolution of a target tophus · participants with tophi in gout

Lesinurad 200 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).

1 finding from 1 review

Lesinurad 400 mg plus allopurinol vs placebo plus allopurinol

Proportion with complete resolution of a target tophus · participants with tophi in gout

Lesinurad 400 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).

1 finding from 1 review

Pegloticase every two weeks (biweekly) vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Proportion with complete resolution of a target tophus · participants with tophi in gout

Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Joint pain reduction ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

NSAIDs vs placebo

Participant‐reported pain relief of 50% or greater · acute gout

NSAIDs may leads to higher pain: ≥ 50% improvement in pain (spontaneous pain at 24 hours) compared with placebo (low certainty).

1 finding from 1 review

NSAIDs vs placebo

Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout

NSAIDs showed no clear difference in inflammation: swelling compared with placebo (low certainty).

1 finding from 1 review

NSAIDs vs placebo

Function: ≥ 50% improvement in pain with movement at 24 hours · acute gout

NSAIDs showed no clear difference in function: ≥ 50% improvement in pain with movement at 24 hours compared with placebo (low certainty).

1 finding from 1 review